Blood Stream Infections
Micrologix Signs license agreement with Fujisawa
Published in Blood Weekly, September 5th, 2002
Micrologix Biotech, Inc., a biotechnology company focused on anti-infective drug development, and Fujisawa Healthcare, Inc., the U.S. subsidiary of Fujisawa Pharmaceutical Co., Ltd., a global developer and marketer of proprietary pharmaceutical products, have entered into a collaboration and license agreement for the codevelopment and commercialization of Micrologix's proprietary cationic peptide product candidate, MBI 226, for the prevention of central venous catheter (CVC) - related blood stream infections.
Micrologix will receive up to US$21 million in up-front and milestone payments, as well as a royalty of 20% on sales of the product.
Fujisawa...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2002-09-05)
More Articles from Blood Weekly
- Leukemia
New screening test may help predict relapse - Stem Cell Transplantation
Cyclosporine adds little benefit to prednisone treatment for graft-versus-host disease - PCR Technology
Molecular diagnostics and the future of healthcare discussed at AACC meeting - Stem Cell Research
Cycling fetal progenitors capable of efficient engraftment - Transplant Medicine
Bone marrow cell transplantation could save limbs - Appointments
Serologicals Corp. names James J. Kramer, PhD, VP, plasma operations - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
